FORM OF SERIES B COMMON STOCK PURCHASE WARRANT NEUROTROPE BIOSCIENCE, INC.Warrant Agreement • September 30th, 2020 • Neurotrope, Inc. • Pharmaceutical preparations • New York
THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ______________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after two business days after the public announcement of the consummation of the spin off (the "Spin Off”) contemplated by the Merger Agreement (as defined in the Warrant Amendment Agreement, dated as of ________, 2020, by and between Neurotrope, Inc. and the Holder) (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on _______ [ ], 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Neurotrope BioScience, Inc., a Delaware corporation (the “Company”), up to ________________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of common stock (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal t
WARRANT AMENDMENT AGREEMENTWarrant Amendment Agreement • September 30th, 2020 • Neurotrope, Inc. • Pharmaceutical preparations • New York
This Warrant Amendment Agreement (this “Agreement”), dated as of September __, 2020, is by and between Neurotrope, Inc., a Nevada corporation (the “Company”), and the undersigned holder (the “Holder”) of Series F warrants to purchase shares of the Company’s common stock, $0.0001 par value (the “Common Stock”).
SECOND AMENDMENT TO AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • September 30th, 2020 • Neurotrope, Inc. • Pharmaceutical preparations • New York
THIS SECOND AMENDMENT TO AGREEMENT AND PLAN OF MERGER, is made and entered into as of the 30th day of September, 2020 (the “Amendment”) by and among PETROS PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), PM MERGER SUB 1, LLC, a Delaware limited liability company and a direct wholly owned subsidiary of Parent (“Merger Sub 1”), PN MERGER SUB 2, INC., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Merger Sub 2” and, together with Merger Sub 1, the “Merger Subs”), NEUROTROPE, INC., a Nevada corporation (“Neurotrope”), and METUCHEN PHARMACEUTICALS LLC, a Delaware limited liability company (“Company”).
